陇神戎发(300534) - 2023 Q3 - 季度财报

Financial Performance - Revenue for Q3 2023 reached ¥220,834,019.31, a 77.19% increase compared to the same period last year[5] - Net profit attributable to shareholders was ¥14,634,388.27, reflecting a 91.87% year-over-year growth[5] - The company reported a basic earnings per share of ¥0.0482, up 92.03% from the previous year[5] - The total operating revenue for the third quarter of 2023 reached CNY 812,306,262.81, a significant increase from CNY 401,104,308.02 in the same period last year, representing a growth of approximately 102.5%[27] - The net profit for the third quarter of 2023 reached CNY 62,932,999.22, a significant increase from CNY 19,056,957.67 in the same period last year, representing a growth of approximately 230.5%[28] - Operating profit for the third quarter was CNY 74,610,054.50, compared to CNY 24,580,944.93 in the previous year, indicating an increase of about 203.5%[28] - The company’s basic and diluted earnings per share for the third quarter were both CNY 0.1544, compared to CNY 0.0528 in the same quarter last year, representing an increase of approximately 192.3%[29] - Total comprehensive income for the third quarter was CNY 62,932,999.22, compared to CNY 19,056,957.67 in the previous year, reflecting a growth of about 230.5%[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,323,425,482.21, an increase of 1.65% from the end of the previous year[5] - The total assets of the company as of September 30, 2023, amounted to CNY 1,323,425,482.21, up from CNY 1,301,901,629.42 at the beginning of the year, reflecting a growth of about 1.6%[25] - Total liabilities increased to CNY 635,850,419.50 from CNY 421,620,965.93, indicating a rise of approximately 50.8%[25] - The company's equity attributable to shareholders decreased to CNY 616,774,145.06 from CNY 827,265,085.07, representing a decline of about 25.5%[25] Cash Flow - The company’s operating cash flow net amount for the year-to-date was ¥38,433,800, a 49.33% increase compared to the same period last year[5] - The net cash flow from operating activities increased by 49.33% year-on-year, driven by higher cash receipts from sales of goods and services[12] - The company reported cash inflows from operating activities of CNY 856,953,891.22, compared to CNY 499,251,667.85 in the previous year, marking a growth of about 71.8%[30] - Cash outflows from operating activities totaled CNY 818,520,001.01, up from CNY 473,514,617.29, resulting in a net cash flow from operating activities of CNY 38,433,890.21, an increase of 49.0% year-over-year[31] - The company’s cash and cash equivalents decreased to CNY 263,444,470.55 as of September 30, 2023, down from CNY 369,244,036.02 at the beginning of the year, reflecting a decline of approximately 28.6%[22] - The company’s cash and cash equivalents at the end of the period were CNY 263,444,470.55, compared to CNY 134,756,366.82 at the end of the previous year, indicating an increase of approximately 95.1%[31] Expenses and Investments - The company’s sales expenses increased by 162.72% year-over-year, primarily due to increased market expansion costs[11] - The company’s investment income decreased by 100%, indicating a reduction in investment returns during the reporting period[11] - Research and development expenses rose to CNY 20,650,952.75, up from CNY 16,256,471.85, reflecting a year-over-year increase of approximately 27.5%[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,996[14] - Gansu Pharmaceutical Investment Group Co., Ltd. holds 29.93% of the shares, making it the largest shareholder[14] Corporate Developments - The company obtained a drug re-registration approval notice for the product "Mahuang Xingren Zhike Jiao Nang" on January 5, 2023[15] - The company completed the acquisition of Gansu Puan Pharmaceutical Co., Ltd. on February 8, 2023, with the transfer of 70% of the shares[16] - The company appointed Qian Shuangxi as the new general manager on March 10, 2023[18] - The company appointed Zhao Zhengcai as the new Vice President and Chief Financial Officer following the resignation of Liu Maosheng[19] - The company’s subsidiary, Gansu Puan Pharmaceutical Co., Ltd., underwent a change in legal representative and obtained new licenses, indicating ongoing operational adjustments and compliance efforts[20] - The company expanded its production line for "Hefei" and obtained a new production license on February 15, 2023[17] Inventory and Borrowings - Inventory increased by 47.73% compared to the beginning of the period, as the company ramped up production to ensure supply during peak sales[9] - Short-term borrowings doubled, reflecting a new ¥30 million loan for working capital[9]